新补骨脂异黄酮
| 中文名称 | 新补骨脂异黄酮 |
|---|---|
| 中文同义词 | NEOBAVAISOFLAVONE 新补骨脂异黄酮;新补骨脂异黄酮, 来源于补骨脂;新补骨脂异黄酮(标准品);新补骨脂异黄酮, >99%;新补骨脂异黄酮NEOBAVAISOFLAVONE;7-羟基-3-[4-羟基-3-(3-甲基-2-丁烯-1-基)苯基]-4H-1-苯并吡喃-4-酮;7-羟基-3-(4-羟基-3-(3-甲基丁-2-烯-1-基)苯基)-4H-苯并吡喃-4-酮;新补骨脂异黄酮对照品 |
| 英文名称 | 3''-PRENYLDAIDZEIN |
| 英文同义词 | Neobavaisoavone;7-Hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)phenyl)-4H-chromen-4-one;4',7-Dihydroxy-3'-(3-methyl-2-butenyl)isoflavone;Neobavaisoflavone, >99%;7-hydroxy-3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one;7-Hydroxy-3-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-4H-1-benzopyran-4-one;Neobavaisoflavone, 98%, from Psoralea corylifolia L.;4H-1-Benzopyran-4-one, 7-hydroxy-3-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]- |
| CAS号 | 41060-15-5 |
| 分子式 | C20H18O4 |
| 分子量 | 322.35 |
| EINECS号 | |
| 相关类别 | 标准品-对照品;分析试剂标准品;中药对照品;标准品;植物提取物;对照品;植提标准品;对照品-中药对照品;黄酮;标准品 -中药标准品;Iso-Flavones;标准品，对照品;合成中间体 |
| Mol文件 | 41060-15-5.mol |
| 结构式 |  |
新补骨脂异黄酮 性质
| 熔点 | 195-196℃ |
|---|---|
| 沸点 | 545.0±50.0 °C(Predicted) |
| 密度 | 1.279 |
| 储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
| 溶解度 | DMF：20mg/mL； DMF:PBS (pH 7.2) (1:4)：0.1 mg/mL；二甲基亚砜：10mg/mL；乙醇：1mg/mL |
| 形态 | 黄色固体 |
| 酸度系数(pKa) | 6.92±0.20(Predicted) |
| 颜色 | 白色至浅黄色至浅橙色 |
| 最大波长(λmax) | 300nm(lit.) |
| 主要应用 | food and beverages |
| InChI | 1S/C20H18O4/c1-12(2)3-4-14-9-13(5-8-18(14)22)17-11-24-19-10-15(21)6-7-16(19)20(17)23/h3,5-11,21-22H,4H2,1-2H3 |
| InChIKey | OBGPEBYHGIUFBN-UHFFFAOYSA-N |
| SMILES | OC1=CC=C(C(C(C2=CC(CC=C(C)C)=C(O)C=C2)=CO3)=O)C3=C1 |
DNA polymerase
Neobavaisoflavone (1-50 μM; 20 h) decreases NO (ED
50
=25 μM) and cytokine (ED
50
s=23.11, 5.03, 5.23, 5.26 and 18.80 μM for IL-1β, IL-6, IL-12p40, IL-12p70 and TNF-α, respectively) production in LPS plus IFN-γ-stimulated RAW264.7 macrophages.
Neobavaisoflavone (1-100 μM; 30 min) decreases the chemiluminescence in PMA-stimulated RAW264.7 macrophages, with an ED
50
of 19.94 μM in activated RAW264.7 cells.
Neobavaisoflavone (1-100 μM); 20 h) has no effect on the viability and is not toxic to RAW264.7 cells.
Neobavaisoflavone (20-50 μM; 48 h) inhibits prostate cancer cell proliferation by inducing cytotoxicity and apoptosis in a dose-dependent manner.
Neobavaisoflavone (2-8 μM; 7 d) inhibits RANKL‐mediated osteoclastogenesis in bone marrow monocytes (BMMCs) and RAW264.7 cells dose dependently at the early stage.
Neobavaisoflavone (30 mg/kg; i.p. for 6 weeks) inhibits osteoclastogenesis, promotes osteogenesis and ameliorates bone loss in ovariectomized mice.
| Animal Model: | C57BL/6 female mice (8 weeksd; 20-25 g) were removed bilateral ovaries |
| Dosage: | 30 mg/kg |
| Administration: | I.p. for 6 weeks |
| Result: | Attenuated bone loss by inhibiting osteoclast activation and promoting osteogenesis in ovariectomized mice. |
安全信息
| WGK Germany | WGK 3 |
|---|---|
| RTECS号 | DJ3100028 |
| 海关编码 | 2932.99.6100 |
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | N1122 | 新补骨脂异黄酮 Neobavaisoflavone | 41060-15-5 | 5mg | 190元 |
| 2025/12/22 | N1122 | 新补骨脂异黄酮 Neobavaisoflavone | 41060-15-5 | 25mg | 560元 |